Sarepta secures source of plasmid DNA for gene therapy programs

Sarepta Therapeutics (NASDAQ:SRPT) inks a long-term agreement with Aldevron for the supply of plasmid DNA to support its gene therapy programs.

Aldevron will supply GMP-grade plasmid for Sarepta’s DMD and Limb-girdle muscular dystrophy (LGMD) programs as well as plasmid source material for future programs, including Charcot-Marie-Tooth, MPS IIIA, Pompe and other CNS disorders.

Financial terms are not disclosed.

https://seekingalpha.com/news/3419946-sarepta-secures-source-plasmid-dna-gene-therapy-programs